Expert review of anti-infective therapy
-
Community-acquired pneumonia (CAP) is the leading cause of death due to bacterial infection. It accounts for 10 million physician office visits in the USA annually. However, 80% of these are managed in the community, usually with oral antibiotic therapy. ⋯ Gemifloxacin is a potent agent, active against pneumococci and atypical pathogens. Administered once daily for 5 days, gemifloxacin is highly efficacious and well tolerated. Gemifloxacin administered for 5-7 days is a cost effective and safe alternative to both parenteral and oral antimicrobials, which may not cover the emerging resistant respiratory pathogens.
-
Expert Rev Anti Infect Ther · Aug 2008
Toll-like receptors: their roles in bacterial recognition and respiratory infections.
Although respiratory infections cause significant morbidity and mortality throughout the world, the immunologic factors that mediate host susceptibility to these infections remain poorly understood. The lung contains a vast surface at the host-environment interface and acts as a crucial barrier to invading pathogens. ⋯ In this review, we will summarize current knowledge of TLRs and their bacterial ligands and explore their role in respiratory infections. Moreover, we will highlight recent advances in the role of TLRs in pulmonary infections from a human immunogenetics perspective.